Tuberculosis treatment adherence in the era of COVID-19

Christopher K. Lippincott, Allison Perry, Elizabeth Munk, Gina Maltas and Maunank Shah

Abstract

Background In-person directly observed therapy (DOT) is commonly used for tuberculosis (TB) treatment monitoring in the US, with increasing usage of video-DOT (vDOT). We evaluated the impact of COVID-19 on TB treatment adherence, and utilization and effectiveness of vDOT.

Methods We abstracted routinely collected data on individuals treated for TB disease in Baltimore, Maryland between April 2019 and April 2021. Our primary outcomes were to assess vDOT utilization and treatment adherence, defined as the proportion of prescribed doses (7 days/week) verified by observation (in-person versus video-DOT), comparing individuals in the pre-COVID and COVID (April 2020) periods.

Results Among 52 individuals with TB disease, 24 (46%) received treatment during the COVID-19 pandemic. vDOT utilization significantly increased in the COVID period (18/24 [75%]) compared to pre-COVID (12/28 [43%], p = 0.02). Overall, median verified adherence was similar pre-COVID and COVID periods (65% versus 68%, respectively, p = 0.96). Adherence was significantly higher overall when using vDOT (median 86% [IQR 70–98%]) compared to DOT (median 59% [IQR 55–64%], p < 0.01); this improved adherence with vDOT was evident in both the pre-COVID (median 98% vs. 58%, p < 0.01) and COVID period (median 80% vs. 62%, p = 0.01).

Conclusion vDOT utilization increased during the COVID period and was more effective than in-person DOT at verifying ingestion of prescribed treatment.

Keywords Video DOT, mHealth, Tuberculosis, Medication adherence, Telemedicine

Background

Tuberculosis (TB) remains a public health priority in the United States (US) [1–3]. TB treatment requires a significant investment of public health resources due to prolonged treatment courses with multi-drug regimens which are often complicated by drug toxicity [2]. These challenges can strain treatment adherence therein leading to suboptimal outcomes including treatment failure and drug-resistance [4, 5]. Adherence support interventions are beneficial for patients and promote successful completion of TB treatment [1, 2, 6].

Directly observed therapy (DOT) is a strategy used to monitor TB treatment adherence [2]. While a Cochrane review concluded that DOT “did not provide a solution to poor adherence in TB treatment” [6], within the global community, DOT is a heterogenous strategy with context-dependent definitions, including community- or home-based DOT, which can be administered by trained lay providers, health-care workers, or family members. World Health Organization (WHO) recommends DOT to support patients throughout treatment while not
explicitly as an adherence support intervention [7]. In the US, DOT is under the jurisdiction of local health departments and typically involves a trained healthcare professional supervising a patient while ingesting TB therapy in the home or workplace [2, 8]. This strategy is recommended by the Centers for Disease Control and Prevention (CDC) as standard of care and has been a mainstay of TB case management and adherence monitoring for decades [2]. However, DOT has several limitations including inefficient use of human resources and inability to provide observed dosing on weekends; these challenges are exacerbated in the Coronavirus Disease 2019 (COVID-19) era with limitations on in-person close contact. Novel approaches are needed to improve upon this treatment adherence support strategy.

Video DOT (vDOT) is a modality where digital technology platforms (e.g., smartphone, tablet, computer) are used to verify the observation of a patient, either live or recorded, receiving their TB treatment [9, 10]. WHO have recommended vDOT be considered as an alternative to in-person DOT when technology is readily available to support this approach and CDC developed a toolkit to provide guidance for providers looking to utilize this strategy with their patients [7, 9, 10]. Video-DOT can be implemented synchronously (i.e., live-stream video communication at the time of medication ingestion), or asynchronously (i.e., videos are recorded documenting ingestion, but reviewed at a later time by healthcare workers). Since that time, vDOT has been increasingly utilized in the US, has shown to improve treatment adherence monitoring, in part by allowing for routine observation of weekend doses, and is broadly accepted by staff and patients alike [11–13]. Importantly, vDOT is economically feasible with significant cost-savings over the course of a 6 month treatment course [11, 12].

In early 2020, the onset of the COVID-19 pandemic created a need to continue providing essential healthcare services while adopting social distancing practices to reduce the speed of viral transmission. This spurred a rapid transition towards telehealth clinical services beginning in March and April 2020 across health systems [14]. Since that time, the adoption of telehealth for outpatient clinical services has been massive with an estimated 63-fold increase in Medicare telehealth utilization during the COVID-19 pandemic [15]. However, the adoption of telehealth services for TB treatment adherence monitoring, specifically vDOT, during the COVID-19 pandemic has not been described. Many TB programs suffered worker shortages and health care service disruptions with negative consequences on TB outcomes [16, 17]. In Maryland, where this study was conducted, limitations on in-person contact instituted in April 2020 disrupted usual DOT services and in-person nurse case-management, and some health care workers were task-shifted to COVID-19 response activities. During this time, asynchronous vDOT was increasingly utilized as part of routine care; asynchronous vDOT was implemented by local health departments preferentially to synchronous video-conferencing for adherence monitoring due to logistical considerations related to health care worker availability and to offer patients flexibility to determine their own timing of medication ingestion (e.g., evening ingestion outside of business hours). Thus, we performed a retrospective cohort study to understand the impact of the COVID-19 pandemic on TB treatment adherence, and the utilization and effectiveness of vDOT before and during the COVID-19 pandemic at the Baltimore City Health Department (BCHD) TB Program.

Methods
We conducted a retrospective observational cohort study of patients receiving routine TB treatment at the BCHD TB Program. The study protocol was approved by the Johns Hopkins Medicine Institutional Review Board.

Study population
From April 2019 to April 2021, eligible patients included those receiving treatment for TB disease in Baltimore, Maryland. Routinely collected data was abstracted from eligible patients ≥18 years of age who were then classified into the pre-COVID period and COVID period. Individuals were classified as receiving treatment in the COVID period if they started therapy after April 2020, or received at least three months of therapy after April 2020 to capture those who may have initiated prior to April 2020 but received significant care during the COVID period. As part of routine clinical care at BCHD, all patients have treatment adherence monitored using DOT (in-person adherence verification through observation in person’s home or workplace 5 days per week excluding weekends and government holidays) or vDOT (7 days per week) according to local protocols using a shared decision-making paradigm between patients and TB clinic providers. Patients and providers changed treatment monitoring strategies as needed based on individualized considerations; there were no restrictions or exclusions on vDOT usage based on prior adherence or treatment completion, sputum smear-status, or drug resistance.

vDOT application usage
The vDOT system (emocha mobile health, Baltimore, MD) is comprised of a smartphone/tablet application (app) used by patients, and a web-based dashboard used by the TB clinic. The patient-side app reminds patients to take their medications based on the prescribed dosing schedule (e.g., once per day) by the clinician. For non-English speaking patients, the app can deliver content in multiple languages customized to the patient. The app
allows a secure/encrypted video recording to be taken as the patient ingests the prescribed medications, according to the patient’s schedule. Encrypted videos and data are transmitted to a secure cloud-based server within seconds and subsequently deleted from the patient’s phone, ensuring privacy. The videos can then be asynchronously viewed by TB clinic staff, where patient medication ingestion does not have to occur simultaneously with adherence verification, through the emocha web interface. This typically occurs on the next business day where the clinician is prompted to make a determination as to adherence with DOT after watching each video.

**Variable and outcome definitions**

vDOT utilization was defined as the proportion of patients who received any vDOT for treatment of TB disease. Overall adherence was defined as the proportion of all prescribed doses (i.e., 7 days per week) that could be documented as verified through observation, irrespective of adherence monitoring modality (i.e., traditional DOT or vDOT). Prescribed doses that could not be confirmed as ingested were recorded to be ‘missed’ or ‘self-administered’, based on chart documentation. In general, doses were documented in patient charts as ‘missed’ by the clinic if a patient missed a scheduled in-person DOT dose or failed to submit a video (with no other communication with the clinic regarding self-administration) on a prescribed dosing day. By contrast, the clinic documented doses as ‘self-administered’ if they were dispensed but had no observation modality scheduled (e.g., weekend or holiday doses dispensed by the clinic ahead of time with no in-person DOT available, or patient self-reporting ingestion without video when receiving vDOT). In addition to overall adherence, we reported adherence stratified by monitoring strategy. vDOT adherence was therefore defined as the proportion of prescribed doses that were verified through video observation among patients receiving vDOT. In-person DOT adherence was defined as the proportion of prescribed doses (over 7 days per week) verified through in-person observation among patients who received DOT.

**Statistical analysis**

Primary outcomes were stratified by the pre-COVID and COVID periods and included vDOT utilization and treatment adherence. Standard descriptive statistics were used to characterize the study cohort. Chi-square test and two-sample t-tests were used to compare vDOT utilization and treatment adherence between DOT and vDOT overall and in the pre-COVID and COVID periods. Multivariable logistic regression was used to understand the relationship between patient characteristics with utilization of vDOT and treatment adherence. All analyses were performed with Stata 16.

**Table 1** Patient Demographics (n = 52)

|                    | Overall | Pre-COVID | COVID | p   |
|--------------------|---------|-----------|-------|-----|
| Age in years, median (IQR) | 43 (30–57) | 39 (29–54) | 53 (37–60) | 0.082 |
| Sex, n (%)         |         |           |       |     |
| Male               | 33 (63%) | 19 (68%)  | 14 (59%) | 0.477 |
| Female             | 19 (37%) | 9 (32%)   | 10 (42%) |     |
| Born outside US, n (%) |     |           |       |     |
| No                 | 23 (44%) | 10 (36%)  | 13 (54%) | 0.182 |
| Yes                | 29 (56%) | 18 (64%)  | 11 (46%) |     |
| Ethnicity, n (%)   |         |           |       |     |
| Not hispanic       | 31 (60%) | 12 (43%)  | 19 (79%) | 0.025 |
| Hispanic           | 10 (19%) | 7 (25%)   | 3 (13%)  |     |
| Unknown/not reported | 11 (21%) | 9 (32%)   | 2 (8%)  |     |
| Race, n (%)        |         |           |       |     |
| Asian              | 9 (17%)  | 4 (14%)   | 5 (21%)  | 0.364 |
| Black/African American | 31 (60%) | 15 (54%)  | 16 (67%) |     |
| White              | 6 (12%)  | 4 (14%)   | 2 (8%)   |     |
| Unknown/not reported | 6 (12%)  | 5 (18%)   | 1 (4%)   |     |
| Experiencing homelessness, n (%) |   |           |       | 0.573 |
| No                 | 45 (87%) | 22 (79%)  | 23 (96%) |     |
| Yes                | 5 (10%)  | 4 (14%)   | 1 (4%)   |     |
| Unknown/not reported | 2 (4%)  | 2 (7%)    | 0 (0%)   | 0.275 |
| HIV-infected, n (%) |         |           |       |     |
| No                 | 51 (98%) | 28 (100%) | 23 (96%) |     |
| Yes                | 1 (2%)   | 0 (0%)    | 1 (4%)   |     |
| Tuberculosis classification, n (%) |   |           |       | 0.809 |
| Pulmonary           | 30 (58%) | 15 (54%)  | 15 (63%) |     |
| Extrapulmonary      | 17 (33%) | 10 (36%)  | 7 (29%)  |     |
| Both               | 5 (10%)  | 3 (11%)   | 2 (8%)   |     |
| AFB smear, n (%)   |         |           |       | 0.290 |
| Smear-negative     | 29 (56%) | 18 (64%)  | 11 (46%) |     |
| Smear-positive     | 22 (42%) | 9 (32%)   | 13 (54%) |     |
| Unknown/not reported | 1 (2%)  | 1 (4%)    | 0 (0%)   |     |

**Results**

A total of 52 patients received treatment for active TB during the study period, of whom 24 (46%) received therapy in the COVID period. Most patients were men (33, 63%), Black/African American (31, 60%), and born outside the US (29, 56%). Nearly all patients (51, 98%) were HIV-uninfected. Thirty patients were classified as having pulmonary TB (58%), 17 (33%) patients had extrapulmonary TB, and 5 (10%) patients had both. There was no difference in the distribution of pulmonary and extrapulmonary TB (p=0.81) or AFB smear-status (p=0.29) in the pre-COVID and COVID periods. (Table 1)

**Reach of vDOT**

TB treatment was monitored for all patients with vDOT, in-person DOT, or both. Overall vDOT was utilized for a portion of TB treatment monitoring for 58% (30/52) of patients while the remaining patients (42%,
Table 2  Tuberculosis Treatment Adherence Before and During the COVID-19 Pandemic

|                  | Overall | Pre-COVID | COVID | p   |
|------------------|---------|-----------|-------|-----|
| vDOT utilization, n (%) | 30/52 (58%) | 12/28 (43%) | 18/24 (75%) | 0.019 |
| Overall adherence (irrespective of modality), median (IQR) | 66% (57–83%) | 68% (57–84%) | 0.959 |
| Adherence by modality, median (IQR) | vDOT adherence | 86% (70–98%) | 98% (78–99%) | 0.022 |
| DOT adherence | 59% (55–64%) | 58% (53–61%) | 0.759 |
| Missed doses by modality, median (IQR) | vDOT missed | 5% (0–16%) | 2% (0–17%) | 0.555 |
| DOT missed | 1% (0–5%) | 2% (0–7%) | 0.276 |
| Self-administered doses by modality, median (IQR) | vDOT self-administered | 1% (0–7%) | 0 (0–0%) | 0.026 |
| DOT self-administered | 38% (35–44%) | 38% (35–44%) | 0.941 |

1. Adherence was significantly higher when comparing vDOT to DOT overall (p<0.001), during the pre-COVID period (p<0.001), and during the COVID period (p=0.012).
2. Missed doses were significantly higher when comparing vDOT to DOT overall (p=0.008) and during the COVID period (p=0.006). Missed doses were similar when comparing vDOT to DOT in the pre-COVID period (p=0.321).
3. Self-administered doses were significantly lower when comparing vDOT to DOT overall (p<0.001), during the pre-COVID period (p<0.001), and during the COVID period (p<0.001).

22/52 received treatment monitoring with in-person DOT only. Among 30 individuals receiving vDOT, 14 (47%) received vDOT for their entire treatment course within the BCHD TB program. A significantly greater proportion of patients utilized vDOT compared to the pre-COVID period (18/24, 75%), compared to the pre-COVID period (12/28, 43%, p=0.02). (Table 2) Among individuals receiving some form of vDOT, the median proportion of all prescribed treatment monitored by vDOT was 75%, (IQR 53–92%); there was a trend towards a greater proportion of therapy monitored by vDOT comparing pre-COVID and COVID periods (68% vs. 73%, p=0.58). In a multivariable analysis, vDOT utilization was most influenced by age (age >65 years, AOR 0.011 [0.0002–0.62] [1/8 (12.5%)], p=0.028, compared to age <30 years [10/15 (67%)]) and the onset of the COVID-19 pandemic (AOR 16.6 [1.35–203] for COVID period compared to pre-COVID period, p=0.03), and was not influenced by birth country (AOR 1.86 [0.18–19.2] for non-USB compared to USB), sex (AOR 1.5 [0.15–15.9]) for males compared to female), homelessness (AOR 4.65 [0.1–211]), employment (AOR 5.5 [0.7–43]), or smear-status (AOR 0.42[0.05–3.6]).

Effectiveness of vDOT compared to in-person DOT
Median overall verified adherence (irrespective of monitoring strategy) was 66% (IQR 57–84%), and was similar in the pre-COVID (65%, IQR 57–83%) and COVID (68%, IQR 57–84%) periods (p=0.96). Overall, the proportion of prescribed doses (seven days/week for all patients) verified through observation was significantly higher when utilizing vDOT (median 86% [IQR 70–98%]), compared to in-person DOT (median 59% [IQR 55–64%], p<0.01). These findings were driven by the high proportion of self-administered doses when using in-person DOT (median 38% [IQR 35–44%] compared to periods when patients were using vDOT (median 1% [IQR 0–7%]) (p<0.01). (Table 2)

Verified adherence in pre-COVID and COVID periods
Verified adherence was higher when using vDOT compared to in-person DOT in both the pre-COVID (median 98% vs. 58% for vDOT and DOT, respectively, p<0.01) and COVID period (median 80% vs. 62% for vDOT and DOT, respectively, p=0.01). When comparing the pre-COVID and COVID period adherence for each treatment monitoring strategy, verified adherence was similar when using in-person DOT (median 58% vs. 62% for the pre-COVID and COVID periods, respectively, p=0.76) and declined when using vDOT (median 98% vs. 80%, for the pre-COVID and COVID periods, respectively, p=0.02). The latter difference was primarily attributable to an increase in the number of doses that were self-administered when using vDOT between the pre-COVID and COVID periods (median 0% vs. 6%, respectively, p=0.03). Self-administered doses (i.e., weekends and holidays) when using in-person DOT remained high and stable across the pre-COVID and COVID periods (median 38% vs. 37%, respectively, p=0.94). (Table 2)

Overall, in a multivariable analysis, verified adherence was most influenced by receipt of vDOT and was 18% higher among those receiving vDOT compared to those not receiving vDOT; verified adherence was not associated with age, sex, birth country, homelessness, or study period.

Discussion
The COVID-19 pandemic and associated lockdowns and staffing shifts led to significant disruption in healthcare delivery within TB programs including the Baltimore City Health Department, particularly related to traditional approaches to treatment verification using in-person DOT [14, 15]. With diminished ability to deliver
in-person DOT, our study confirmed that there was a significant increase in vDOT utilization in the COVID period. Nonetheless, despite these COVID-related disruptions, this retrospective cohort study found that overall verified treatment adherence was not impacted by the COVID-19 pandemic. Moreover, we found that in both the pre-COVID and COVID period, vDOT usage led to significantly higher verification of treatment compared to in-person DOT.

Overall, there have been shifting paradigms in TB treatment monitoring towards patient-centered approaches such as vDOT. Our study suggests that the COVID-19 pandemic may have accelerated these transitions. In Baltimore, prior to COVID-19, less than half of all patients were monitored using vDOT. With limitations on in-person contact during much of 2020 and 2021, we found that nearly three-quarters of patients were subsequently monitored using vDOT. Age greater than 65 was associated with decreased vDOT utilization, a finding previously noted in the vDOT literature, which may suggest that familiarity with smartphone/tablet technology may impact patient acceptance of this strategy [18]. Despite this vDOT transition, there was no decline in treatment adherence overall in the TB program; rather, individuals monitored with vDOT had a higher proportion of prescribed doses verified compared to in-person DOT in both the pre-COVID and COVID periods.

Our study therefore highlights particular limitations with in-person DOT in monitoring TB treatment, which is increasingly prescribed 7 days per week. We found that vDOT was more effective than DOT at verifying treatment adherence, and that less than two-thirds of prescribed therapy were able to be verified when using in-person DOT—reflecting logistical challenges with in-person verification during weekends and holidays. Consequently, we report that a large proportion of prescribed therapy is given with self-administration when using in-person DOT.

We also identified other challenges experienced by TB programs during the COVID-19 pandemic [16, 17]. Specifically, we found a modest decline in verified adherence when using vDOT, when comparing the pre-COVID (98%) to COVID (80%) period. This decline in vDOT verified adherence was driven by a significant increase in self-administered vDOT doses in the COVID period. The reasons for this finding are unclear, but were felt by the clinic staff to be attributable to individual level delays in transitioning and initiating vDOT due to reduced opportunities for in-person training on the vDOT system, or delays in troubleshooting any technical issues that may have been experienced by patients.

There are several limitations with this study. Since the study is an analysis of the real-world implementation of vDOT in a city health department, patients were not randomized to one modality or another. This study was relatively small (n=52) which may have limited our power to detect some differences in treatment adherence and vDOT utilization. Although we report significant differences of verified adherence between vDOT and in-person DOT, the study was not designed to draw a definitive conclusion in this regard for all populations. Selection of patients for vDOT versus in-person DOT were made by clinic staff based on individualized considerations, and reflect routine clinical practices. While vDOT was utilized by a significant majority of patients in the COVID period, additional qualitative assessments are needed to fully understand patient and provider perspectives associated with this transition from in-person DOT. Overall, vDOT had been available in the BCHD TB program since approximately 2016. Nonetheless, vDOT utilization increases appeared to be influenced by the COVID-19 pandemic. However, we cannot rule out alternative factors including increasing comfort and experience with the vDOT platform that may also have led to progressive increases in vDOT utilization over time.

**Conclusion**

In conclusion, despite the significant disruption of healthcare activities during the COVID-19 pandemic, verified TB treatment adherence at the BCHD was sustained in the setting of increased vDOT utilization. Verified TB treatment was significantly higher with vDOT and adds another data point to the growing literature showing that vDOT improves upon in-person DOT for adherence monitoring and is readily accepted by patients [11–13, 18, 19]. It should be recognized that in-person DOT remains an important strategy for selected patients and can be coupled with other in-person adherence support interventions (such as nurse counseling and monitoring) [2, 7]. In this study, we found that a minority of patients continued to use in-person DOT during the COVID-19 period due to individualized circumstances. Nonetheless, vDOT has intrinsic advantages for documentation of adherence in allowing treatment verification on weekends and holidays, allowing dosing according to patient’s schedules, and potentially reducing stigma. Studies should continue to explore the implementation of this important strategy in real-world settings.

**List of abbreviations**

- AOR: adjusted odds ratio
- App: application
- BCHD: Baltimore City Health Department
- CDC: Centers for Disease Control and Prevention
- COVID-19: Coronavirus Disease 2019
- DOT: directly observed therapy
- IQR: interquartile ratio
- TB: tuberculosis
- US: United States
- vDOT: video DOT
- WHO: World Health Organization
Acknowledgements
None.

Authors’ contributions
M.S. conceptualized and designed the study. M.S., E.M., and G.M. contributed to data collection and database management. C.L., A.P., and M.S. contributed to data analysis and interpretation of the results. C.L. and M.S. wrote the manuscript and A.P., E.M., and G.M. edited the manuscript. All authors reviewed the final manuscript.

Funding
This work was supported by the Small Business Innovation Research (SBIR) program at the National Institutes of Health (NIH; Bethesda, MD, USA) awarded to emocha Mobile Health Inc. [grant number R44MD010521].

Data Availability
The datasets generated and/or analyzed during the current study are not publicly available in the absence of a Data Transfer Agreement due to data sharing policies from Johns Hopkins University, but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study protocol was approved by the Johns Hopkins Medicine Institutional Review Board (IRB00174219). Informed consent was waived by the Johns Hopkins Medicine Institutional Review Board due to the retrospective observational nature of this study. All methods and procedures were approved by the IRB and carried out in accordance with the IRBs’ guidelines and regulations.

Consent for publication
Not applicable.

Competing interests
MS are among the inventors of the vDOT technology licensed to emocha Mobile Health Inc. Under a license agreement between emocha Mobile Health Inc. and the Johns Hopkins University (JHU, Baltimore, MD, USA), MS and JHU are entitled to royalties related to technology described in this study. Specific to this study, MS did not and will not receive royalties or compensation from emocha Mobile Health Inc. (Baltimore, MD, USA). Also, JHU owns equity in eMocha. This arrangement has been reviewed and approved by JHU in accordance with its conflict of interest policies. As per JHU IRB and Conflicts of Interest office (COI), conflicted study team members (MS) were excluded from accessing the original data set. Oversight of data management, including primary analyses and audit of all data analyses, were done by non-conflicted designees (GM, EM, CL), as approved by the JHU IRB and COI office. AP, GM, EM and CL do not have any conflict of interest.

Received: 20 June 2022 / Accepted: 7 October 2022
Published online: 26 October 2022

References
1. CDC. Reported Tuberculosis in the United States. 2020. 2021 [Available from: https://www.cdc.gov/tb/statistics/reports/2020/default.htm.
2. Nahid P, Dorman SE, Alipanah H, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147-e95.
3. Shah M, Dorman SE. Latent Tuberculosis Infection. N Engl J Med. 2021;385(24):2271—80.
4. Pradiptra I, Forsman LD, Bruchfeld J, Hak E, Affenaar JW. Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis. J Infect. 2018;77(6):469—78.
5. Chimeh RA, Gafar F, Pradiptra I, Akkerman OW, Hak E, Affenaar JC, et al. Clinical and economic impact of medication non-adherence in drug-susceptible tuberculosis: a systematic review. Int J Tuberc Lung Dis. 2020;24(8):811—9.
6. Karumbi J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev. 2015(5):CD000343.
7. WHO. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. Geneva; 2017. Report No.: Licence: CC BY-NC-SA 3.0 IGO.
8. CDC. Menu of Suggested Provisions For State Tuberculosis Prevention and Control Laws. 2012 [Available from: https://www.cdc.gov/tb/programs/laws/menu/treatment.htm.
9. WHO. Quick guide to video-supported treatment of tuberculosis. 2020.
10. CDC. Implementing an Electronic Directly Observed Therapy (eDOT) Program: A Toolkit for Tuberculosis (TB) Programs [Available from: https://www.cdc.gov/tb/publications/pdf/tbedottoolkit.pdf.
11. Holzeman SB, Zenilman A, Shah M. Advancing Patient-Centered Care in Tuberculosis Management: A Mixed-Methods Appraisal of Video Directly Observed Therapy. Open Forum Infect Dis. 2018;5(4):eof046.
12. Misraei MD, Farshidpour M, Banks-Tripp D, Hashimi S, Kujoth C, Schraufnagel D. Video directly observed therapy for treatment of tuberculosis is patient-oriented and cost-effective. Eur Respir J. 2015;46(3):871—4.
13. Perry A, Chitnis A, Chin A, Hoffmann C, Chang L, Robinson M, et al. Real-world implementation of video-observed therapy in an urban TB program in the United States. Int J Tuberc Lung Dis. 2021;25(8):655—61.
14. Koonin LM, Hooks B, Tsang CA, Lenoy Z, Farris K, Jolly T, et al. Trends in the Use of Telehealth During the Emergence of the COVID-19 Pandemic - United States, January-March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(43):1595—9.
15. Samson LW, Tuurini W, Sheingold G S.;. Medicare Beneficiaries’ Use of Telehealth in 2020. Trends by Beneficiary Characteristics and Location. U.S. Department of Health and Human Services; 2021. 12/5/2021.
16. Pai M, Kasaeian T, Swaminathan S. Covid-19’s Devastating Effect on Tuberculosis Care - A Path to Recovery. N Engl J Med. 2022.
17. Jaiswal SS, Joshi H, Agrawal P, Joshi H. Management of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2019;68(11):147-e95.
18. Koonin LM, Hoorts B, Tsang CA, Lenoy Z, Farris K, Jolly T, et al. Trends in the Use of Telehealth During the Emergence of the COVID-19 Pandemic - United States, January-March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(43):1595—9.
19. Samson LW, Tuurini W, Sheingold G S.;. Medicare Beneficiaries’ Use of Telehealth in 2020. Trends by Beneficiary Characteristics and Location. U.S. Department of Health and Human Services; 2021. 12/5/2021.
20. Pai M, Kasaeian T, Swaminathan S. Covid-19’s Devastating Effect on Tuberculosis Care - A Path to Recovery. N Engl J Med. 2022.
21. Jaiswal SS, Joshi H, Agrawal P, Joshi H. Management of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2019;68(11):147-e95.
22. Gertein RS, Liu L., Cuevas-Mota J., Collins K., Munoz F., Catanzaro O, et al. Tuberculosis Treatment Monitoring by Video Directly Observed Therapy in 5 Health Districts, California, USA. Emerg Infect Dis. 2018;24(10):1806—15.
23. Holzeman SB, Liu L, Saharashbudhe T, Ambike S, Jagtap D, Sanyal Y, et al. Use of Smartphone-Based Video Directly Observed Therapy (vDOT) in Tuberculosis Care: Single-Arm, Prospective Feasibility Study. JMIR Form Res. 2019;3(3):e13411.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.